TORONTO--(BUSINESS WIRE)--Biovail Corporation (NYSE: BVF) (TSX: BVF) today announced that it has received a Notice of Compliance from the Therapeutic Products Directorate (TPD) for its supplemental New Drug Submission (sNDS) for a new indication for Wellbutrin® XL in Canada – the prevention of major depressive illness with an autumn-winter seasonal pattern.
